---
title: "Medication or procedure — Dr. Chris Thompson | Everself"
url: https://everself.com/thompson/science/medication-vs-procedure/
description: "Medication and procedures both act on appetite, through different levers, and neither has been shown to reset a defended weight. The choice is between two sets of trade-offs rather than between a real fix and a stopgap."
---

Part IV · Decision guide

# Medication or procedure

These are two ways of acting on the same system. Both work, so the comparison that matters is which set of trade-offs you would rather live with.

The short answer

Medication and procedures both act on appetite, through different levers, and neither has been shown to reset a defended weight. Medication works for as long as you take it, while a procedure is a single event with a recovery period and a small risk of serious complications. The choice is between two sets of trade-offs rather than between a real fix and a stopgap.

## First, set aside the version you have probably heard

Many people have heard a tidy story in which medications merely manage symptoms while procedures fix the underlying problem. The story is memorable, and the evidence does not support it.

Current work places GLP-1 receptor agonists and **bariatric surgery** in the same mechanistic category, differing in degree rather than kind.C-IV-09 ESG, which is an endoscopic procedure, is neither of those, and no study extends that comparison to it. What can be said is narrower: all of these act on appetite-related physiology, through different levers. Neither has been shown to reset a defended weight in humans. The Endocrine Society's scientific statement describes such therapies as having the _potential to_ reset the defended level, which is an aspiration rather than a result.C-III-02

You can't out-diet a drifted set point, but the biological pressure to regain can be reduced.

The models that best fit the human evidence explicitly permit a new, lower stable weight.C-III-08 Both options are attempts to reach it, and they differ in how they act, for how long, and at what cost.

## What each one does

**A GLP-1 medication** copies a satiety hormone your gut already makes, engineered to act more strongly and to last far longer than the natural version. Appetite falls, often substantially.C-IV-07

**ESG** reshapes the stomach from the inside so that it holds less and empties more slowly, with half-emptying at about 152 minutes against 89 in controls, a difference still measurable at twelve months.C-IV-05

The levers are different, but both act on the same appetite-related physiology.

## The trade-off that decides it

**With medication, the effect continues only while treatment continues.** After 68 weeks of treatment, at about 17% below starting weight, participants who stopped regained roughly two-thirds of the loss within a year.C-III-09 That is not a failure of the drug but a property of the approach, since the effect depends on the signal being maintained. The practical question is whether long-term, possibly indefinite, treatment is something you want and can afford.

**With a procedure, the intervention is front-loaded.** There is one event, a recovery, and a change that does not depend on remembering a weekly dose. In exchange, you accept about a 2.2% chance of a serious complicationC-IV-12, and you accept that the strongest evidence is weaker than the headline figures suggest: in the one sham-controlled trial, which enrolled 40 MASH patients and ran for 72 weeks, the ESG arm lost 9.5% against 3.9% for sham.C-IV-03

**Neither option escapes the underlying biology.** In the one study that measured it, weight loss raised appetite by roughly 100 calories a day for each kilogram lostC-III-06. Substantial weight loss by any route also takes some lean tissue with itC-IV-08 whichever option you choose, so resistance training, which preserves lean mass, belongs alongside the treatment rather than in place of it.

## Questions worth taking to a consultation

- What happens if I stop the medication, and is stopping part of the plan?
- What is my BMI, and does it fall within the authorized range for the procedure?
- What does each option cost over five years rather than one?
- What is the plan for protecting muscle with either option?
- What happens if I regain?

If a clinician answers any of these with a single number and no caveat, it is reasonable to ask where the number comes from.

## References

1. Schwartz MW, Seeley RJ, et al. Obesity Pathogenesis: An Endocrine Society Scientific Statement. Endocr Rev. 2017. [PMC5546881](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546881/)
2. Polidori D, et al. How Strongly Does Appetite Counter Weight Loss? Obesity. 2016. [PMID 27804272](https://pubmed.ncbi.nlm.nih.gov/27804272/)
3. Speakman JR, et al. Set points, settling points and some alternative models. Dis Model Mech. 2011. [PMID 22065844](https://pubmed.ncbi.nlm.nih.gov/22065844/)
4. Models of body weight and fatness regulation. Phil Trans R Soc B. 2023. [PMC10475878](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475878/)
5. Wilding JPH, et al. Weight regain after withdrawal of semaglutide (STEP 1 extension). 2022. [PMID 35441470](https://pubmed.ncbi.nlm.nih.gov/35441470/)
6. FDA De Novo classification DEN210045, granted 12 July 2022. Indication BMI 30-50. FDA DEN210045
7. Hedjoudje A, Abu Dayyeh BK, Cheskin LJ, et al (incl. Thompson CC). Efficacy and Safety of Endoscopic Sleeve Gastroplasty: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020. [PMID 31442601](https://pubmed.ncbi.nlm.nih.gov/31442601/)
8. Abu Dayyeh BK, et al. MERIT trial: endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity. Lancet. 2022. [PMID 35908555](https://pubmed.ncbi.nlm.nih.gov/35908555/)
9. MASH trial: sham-controlled randomised trial of endoscopic sleeve gastroplasty. 2024. [PMID 39694202](https://pubmed.ncbi.nlm.nih.gov/39694202/)
10. Lopez-Nava G, et al. Endoscopic Sleeve Gastroplasty for Obesity: a Multicenter Study of 248 Patients with 24 Months Follow-Up. Obes Surg. 2017. [PMID 28451929](https://pubmed.ncbi.nlm.nih.gov/28451929/)
11. 21 CFR 876.5983 - classification regulation wording for the endoscopic suturing device. CFR 21 CFR 876.5983
12. Vargas EJ, et al. Effect of endoscopic sleeve gastroplasty on gastric emptying, motility and hormones: a comparative prospective study. Gut. 2023. [PMID 36241388](https://pubmed.ncbi.nlm.nih.gov/36241388/)
13. Lopez-Nava G, et al. Gut hormone changes after endoscopic sleeve gastroplasty. Obes Surg. 2020. [PMID 32193741](https://pubmed.ncbi.nlm.nih.gov/32193741/)
14. Physiology, Obesity Neurohormonal Appetite and Satiety Control. StatPearls. NBK NBK555906
15. Anyiam O, et al. How do glucagon-like peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta-analysis. Obes Rev. 2025. [PMID 40181228](https://pubmed.ncbi.nlm.nih.gov/40181228/)
16. Neeland IJ, et al. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024. [PMID 38937282](https://pubmed.ncbi.nlm.nih.gov/38937282/)
17. Mechanick JI, et al. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obes Rev. 2025. [PMID 39295512](https://pubmed.ncbi.nlm.nih.gov/39295512/)
18. Linge J, et al. Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? Circulation. 2024. [PMID 39401279](https://pubmed.ncbi.nlm.nih.gov/39401279/)
19. Genco A, et al. Intragastric balloon for obesity treatment: results of a multicentric evaluation for balloons left in place for more than 6 months. Surg Endosc. 2015. [PMID 25480604](https://pubmed.ncbi.nlm.nih.gov/25480604/)
20. Vantanasiri K, et al. The Efficacy and Safety of a Procedureless Gastric Balloon for Weight Loss: A Systematic Review and Meta-Analysis. Obes Surg. 2020. [PMID 32266698](https://pubmed.ncbi.nlm.nih.gov/32266698/)
21. Jamal MH, et al. The Safety and Efficacy of Procedureless Gastric Balloon: Elipse Intragastric Balloon with 1-Year Follow-Up Post-removal. Obes Surg. 2019. [PMID 30613935](https://pubmed.ncbi.nlm.nih.gov/30613935/)

[Next How to think about regain](https://everself.com/thompson/science/regain)

## Get started with Everself

- Book a free consultation: https://app.everself.com/signup
- Call (833) 837-7353 or email hello@everself.com
- Everself at a glance, with links to every key page: https://everself.com/llms.txt